BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 29168459)

  • 21. ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach.
    Pelosi G; Fabbri A; Bianchi F; Maisonneuve P; Rossi G; Barbareschi M; Graziano P; Cavazza A; Rekhtman N; Pastorino U; Scanagatta P; Papotti M
    J Thorac Oncol; 2012 Feb; 7(2):281-90. PubMed ID: 22071786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Various Antibody Clones of Napsin A, Thyroid Transcription Factor 1, and p40 and Comparisons With Cytokeratin 5 and p63 in Histopathologic Diagnostics of Non-Small Cell Lung Carcinoma.
    Tran L; Mattsson JS; Nodin B; Jönsson P; Planck M; Jirström K; Botling J; Micke P; Brunnström H
    Appl Immunohistochem Mol Morphol; 2016 Oct; 24(9):648-659. PubMed ID: 26447895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.
    Pelosi G; Haspinger ER; Bimbatti M; Leone G; Paolini B; Fabbri A; Tamborini E; Perrone F; Testi A; Garassino M; Maisonneuve P; de Braud F; Pilotti S; Pastorino U
    Int J Surg Pathol; 2014 Apr; 22(2):136-48. PubMed ID: 24326823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complementary value of electron microscopy and immunohistochemistry in the diagnosis of non-small cell lung cancer: A potential role for electron microscopy in the era of targeted therapy.
    Albero-González R; Munné-Collado J; Pijuan L; Simón M; Gimeno-Beltrán J; Mojal S; Salido M; Clavé S; Juanpere N; Dalmases A; Comerma L; Vázquez I; Sánchez-Font A; Taus Á; Hernández S; Lloveras B; Lloreta Trull J
    Ultrastruct Pathol; 2019; 43(6):237-247. PubMed ID: 31810413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roles of immunohistochemical staining in diagnosing pulmonary squamous cell carcinoma.
    Yan Y; Zhang YX; Fang WF; Kang SY; Zhan JH; Chen N; Hong SD; Liang WH; Tang YN; He DC; Wu X; Zhang L
    Asian Pac J Cancer Prev; 2015; 16(2):551-7. PubMed ID: 25684486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer.
    Nizzoli R; Tiseo M; Gelsomino F; Bartolotti M; Majori M; Ferrari L; De Filippo M; Rindi G; Silini EM; Guazzi A; Ardizzoni A
    J Thorac Oncol; 2011 Mar; 6(3):489-93. PubMed ID: 21258246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue-preserving antibody cocktails to differentiate primary squamous cell carcinoma, adenocarcinoma, and small cell carcinoma of lung.
    Brown AF; Sirohi D; Fukuoka J; Cagle PT; Policarpio-Nicolas M; Tacha D; Jagirdar J
    Arch Pathol Lab Med; 2013 Sep; 137(9):1274-81. PubMed ID: 23289761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ΔNp63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens.
    Zhao W; Wang H; Peng Y; Tian B; Peng L; Zhang DC
    Int J Clin Exp Pathol; 2014; 7(7):4247-53. PubMed ID: 25120805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome.
    Righi L; Vavalà T; Rapa I; Vatrano S; Giorcelli J; Rossi G; Capelletto E; Novello S; Scagliotti GV; Papotti M
    J Thorac Oncol; 2014 Oct; 9(10):1540-6. PubMed ID: 25521399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs.
    Micke P; Mattsson JS; Djureinovic D; Nodin B; Jirström K; Tran L; Jönsson P; Planck M; Botling J; Brunnström H
    J Thorac Oncol; 2016 Jun; 11(6):862-72. PubMed ID: 26872818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diagnosis of lung biopsy employing the 2015 WHO criteria and detection of related oncogenic driver mutations].
    Fang F; Qiao XB; Yang L; Di J; Hu ST; Liu DG; Lyu N
    Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):270-275. PubMed ID: 30955261
    [No Abstract]   [Full Text] [Related]  

  • 32. Endobronchial ultrasound fine-needle aspiration biopsy of pulmonary non-small cell carcinoma with subclassification by immunohistochemistry panel.
    Collins BT
    Cancer Cytopathol; 2013 Mar; 121(3):146-54. PubMed ID: 22927132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contribution of immunohistochemistry in the differential diagnosis of non-small cell lung carcinomas on small biopsy samples.
    Stojsic J; Jovanic I; Markovic J; Gajic M
    J BUON; 2013; 18(1):176-87. PubMed ID: 23613404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemistry in the differential diagnostics of primary lung cancer: an investigation within the Southern Swedish Lung Cancer Study.
    Brunnström H; Johansson L; Jirström K; Jönsson M; Jönsson P; Planck M
    Am J Clin Pathol; 2013 Jul; 140(1):37-46. PubMed ID: 23765532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens.
    Kim MJ; Shin HC; Shin KC; Ro JY
    Ann Diagn Pathol; 2013 Feb; 17(1):85-90. PubMed ID: 23040737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice.
    Rossi G; Pelosi G; Barbareschi M; Graziano P; Cavazza A; Papotti M
    Int J Surg Pathol; 2013 Aug; 21(4):326-36. PubMed ID: 23740564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When tumor doesn't read textbook. Third case of TTF1 and p40 co-expression in the same tumour cells in a non-small cell carcinoma. A potential new entity to consider?
    Spinelli M; Khorshad J; Viola P
    Pathologica; 2019 Jun; 111(2):58-61. PubMed ID: 31388196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for targeted therapies.
    Forest F; Yvorel V; Karpathiou G; Stachowicz ML; Vergnon JM; Fournel P; Tiffet O; Trombert B; Péoc'h M
    Hum Pathol; 2016 Mar; 49():99-106. PubMed ID: 26826416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified.
    Ota T; Kirita K; Matsuzawa R; Udagawa H; Matsumoto S; Yoh K; Niho S; Ishii G; Goto K
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2495-2506. PubMed ID: 31494736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens.
    Rekhtman N; Ang DC; Sima CS; Travis WD; Moreira AL
    Mod Pathol; 2011 Oct; 24(10):1348-59. PubMed ID: 21623384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.